Though the mechanism has yet to be explored, studies have shown that platinum-treatment-resistant epithelial ovarian cancer (EOC) tissue has even greater levels of PARP1 expression, leading to speculation of its potential as a marker for predicting poor prognosis and platinum resistance [87,129]. This evidence concerns the gene PARP1 and ovarian carcinoma.